These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 16375754)

  • 21. Torsadogenic cardiotoxicity of antipsychotic drugs: a structural feature, potentially involved in the interaction with cardiac HERG potassium channels.
    Testai L; Bianucci AM; Massarelli I; Breschi MC; Martinotti E; Calderone V
    Curr Med Chem; 2004 Oct; 11(20):2691-706. PubMed ID: 15544470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs.
    van der Linde H; Van de Water A; Loots W; Van Deuren B; Lu HR; Van Ammel K; Peeters M; Gallacher DJ
    J Pharmacol Toxicol Methods; 2005; 52(1):168-77. PubMed ID: 15935709
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug-induced QT prolongation and proarrhythmia: an inevitable link?
    Ahmad K; Dorian P
    Europace; 2007 Sep; 9 Suppl 4():iv16-22. PubMed ID: 17766320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties.
    Polak S; Wiśniowska B; Brandys J
    J Appl Toxicol; 2009 Apr; 29(3):183-206. PubMed ID: 18988205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing.
    Fish JM; Di Diego JM; Nesterenko V; Antzelevitch C
    Circulation; 2004 May; 109(17):2136-42. PubMed ID: 15078801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome.
    Shimizu W; Antzelevitch C
    J Electrocardiol; 1999; 32 Suppl():177-84. PubMed ID: 10688323
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data.
    Jonker DM; Kenna LA; Leishman D; Wallis R; Milligan PA; Jonsson EN
    Clin Pharmacol Ther; 2005 Jun; 77(6):572-82. PubMed ID: 15961988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of epicardial or biventricular pacing to prolong QT interval and increase transmural dispersion of repolarization: does resynchronization therapy pose a risk for patients predisposed to long QT or torsade de pointes?
    Medina-Ravell VA; Lankipalli RS; Yan GX; Antzelevitch C; Medina-Malpica NA; Medina-Malpica OA; Droogan C; Kowey PR
    Circulation; 2003 Feb; 107(5):740-6. PubMed ID: 12578878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.
    Shantsila E; Watson T; Lip GY
    Europace; 2007 Sep; 9 Suppl 4():iv37-44. PubMed ID: 17766322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
    Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
    J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
    Park E; Gintant GA; Bi D; Kozeli D; Pettit SD; Pierson JB; Skinner M; Willard J; Wisialowski T; Koerner J; Valentin JP
    Br J Pharmacol; 2018 Feb; 175(4):606-617. PubMed ID: 29181850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
    Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
    Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early afterdepolarisations.
    Carlsson L; Abrahamsson C; Andersson B; Duker G; Schiller-Linhardt G
    Cardiovasc Res; 1993 Dec; 27(12):2186-93. PubMed ID: 8313427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ionic mechanisms of acquired QT prolongation and torsades de pointes in rabbits with chronic complete atrioventricular block.
    Tsuji Y; Opthof T; Yasui K; Inden Y; Takemura H; Niwa N; Lu Z; Lee JK; Honjo H; Kamiya K; Kodama I
    Circulation; 2002 Oct; 106(15):2012-8. PubMed ID: 12370228
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation.
    Hanson LA; Bass AS; Gintant G; Mittelstadt S; Rampe D; Thomas K
    J Pharmacol Toxicol Methods; 2006; 54(2):116-29. PubMed ID: 16843688
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of beta-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes.
    Shimizu W; Antzelevitch C
    Circulation; 1998 Nov; 98(21):2314-22. PubMed ID: 9826320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization.
    Roden DM
    Eur Heart J; 1993 Nov; 14 Suppl H():56-61. PubMed ID: 8293755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity.
    De Clerck F; Van de Water A; D'Aubioul J; Lu HR; van Rossem K; Hermans A; Van Ammel K
    Fundam Clin Pharmacol; 2002 Apr; 16(2):125-40. PubMed ID: 12031065
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
    Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
    Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.